Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Authored by: Bernadino JI, Mocroft A., Mallon Patrick W. G., Wallet C, Gerstoft Jan, Russell C, Reiss P. et al.
In: Lancet HIV, 2015